ReviewAdvanced drug delivery reviews2016
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery.
Review in Advanced drug delivery reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1,668 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1,668 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Gold nanoparticles (AuNPs) as emerging anti-inflammatory agents: mechanisms, therapeutic advances, and future directions-a systematic review and meta-analysis.Inflammopharmacology · 2026Pooled it
- Redefining intranasal brain delivery: from nasal entry to meaningful parenchymal and cellular exposure.Drug delivery · 2026Review
- Towards the clinical translation of a novel autophagy inhibitor: Bisaminoquinoline derivative nanoparticles.Biomaterials · 2026Article
- Overcoming hepatic tropism: Precision engineering of lipid nanoparticles for extrahepatic RNA delivery.Materials today. Bio · 2026Review
- Precisely Engineering Biomimetic Nanoparticles via Controlled Cell Membrane Coating.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Synthesis and Optimization of PEG-PLGA Immunotherapeutic Nanoparticles for the Controlled Release of IFNα.AAPS PharmSciTech · 2026Article
- RNA therapeutics: current status and future directions.Signal transduction and targeted therapy · 2026Review
- Nanocarrier mediated microRNA delivery for oral squamous cell carcinoma a scoping review of delivery architecture preclinical efficacy and translational barriers.Discover nano · 2026Review
- Engineering Functional Biomaterials for Targeted and Localized Cancer Drug Delivery: A Structure-Property-Performance Design Perspective.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Nanoplatforms of Pegylated Gold Nanorods Loaded with Non-Steroidal Anti-Inflammatory Drugs: Delivery and Biological Evaluation.Molecules (Basel, Switzerland) · 2026Article
- Selenium Nanoparticles: Novel Synthesis, Characterization, Polymer Functionalization, and Cytotoxicity In Vitro.Molecules (Basel, Switzerland) · 2026Article
- Article
- Article
- Design, Synthesis, and Preclinical Evaluation of Novel Dimeric RM2-Based Radioligands for GRPR-Targeted Breast Cancer Imaging.Molecular pharmaceutics · 2026Article
- Selective organ deposition of nanoparticles directed by metal-organic network coatings.Nature communications · 2026Article
- Advances in vehicles for in situ delivery: From classical vectors to biologically inspired structures.Synthetic and systems biotechnology · 2026Review
- Theranostic π Electron-Stabilized Polymeric Micelles for PET Imaging-Guided Drug Delivery to Tumors.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Advanced Nanomaterials for Chronic Wounds: M.O.I.S.T. Concept-Driven Design Strategy.Advanced healthcare materials · 2026Review
- Nanoparticles for autoimmune diseases: advancing diagnostics and therapeutic solutions.Acta pharmacologica Sinica · 2026Review
- Lipid nanoparticles as active biointerfaces: From membrane interaction to systemic dysregulation.Acta pharmaceutica Sinica. B · 2026Review
1,608 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Coating the surface of nanoparticles with polyethylene glycol (PEG), or "PEGylation", is a commonly used approach for improving the efficiency of drug and gene delivery to target cells and tissues. Building from the success of PEGylating proteins to improve systemic circulation time and decrease immunogenicity, the impact of PEG coatings on the fate of systemically administered nanoparticle formulations has, and continues to be, widely studied. PEG coatings on nanoparticles shield the surface from aggregation, opsonization, and phagocytosis, prolonging systemic circulation time. Here, we briefly describe the history of the development of PEGylated nanoparticle formulations for systemic administration, including how factors such as PEG molecular weight, PEG surface density, nanoparticle core properties, and repeated administration impact circulation time. A less frequently discussed topic, we then describe how PEG coatings on nanoparticles have also been utilized for overcoming various biological barriers to efficient drug and gene delivery associated with other modes of administration, ranging from gastrointestinal to ocular. Finally, we describe both methods for PEGylating nanoparticles and methods for characterizing PEG surface density, a key factor in the effectiveness of the PEG surface coating for improving drug and gene delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.